Drug, bio-affecting and body treating compositions inventions 01/08

20080026983 - Compositions and methods for alleviating joint pain and improving joint flexibility: A Composition and method for administering a nutritional supplement to an individual, e.g., a human or animal, are provided for the alleviation of joint pain, long-lasting relief from joint pain, improvement of joint functioning as well as help to restore joint flexibility through a reduction of inflammation. The nutritional supplement... Agent: Kenyon & Kenyon LLP

20080026982 - Mutant apobec3g molecules for inhibiting replication of hiv: Provided herein are novel APOBEC3G polypeptides having an amino acid substitution at position 129, e.g., P129D in which the polypeptide is capable of resisting proteosomal degradation induced by HIV-Vif. Also provided are isolated nucleic acids encoding the APOBEC3G polypeptides, recombinant vectors comprising the nucleic acids, recombinant host cells comprising the... Agent: Kaliko & Yeager, L.L.C.

20080026981 - Pharmaceutical compositions: A process for micronization of pharmaceutically active agents.... Agent: Novartis Corporate Intellectual Property

20080026980 - Use of agents derived from ceacam1 for the treatment of inflammatory diseases: The use of an agent that selectively modulates cross-linking of biliary glycoprotein polypeptides for the preparation of a pharmaceutical composition for preventing or treatment of a mammal subject afflicted with an inflammatory disease is provided. In particular, a method for preventing or treatment of a mammal subject afflicted with rheumatoid... Agent: Cooper & Dunham, LLP

20080026990 - 18-membered nitrobenzyl- and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites and a process for their preparation: The invention relates to cyclic depsipeptides, especially 18-membered cyclohexadepsipeptides of general formula (I) and the salts thereof, wherein R1 represents nitrobenzyl or R′R″N-benzyl—wherein R′ and R″ independently represent hydrogen, optionally substituted C1-C4-alkyl, formyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkoxycarbonyl, or hydroxy-C1-C2-alkyl-sulfonyl-C1-C2-alkyl, or, together with the nitrogen atom to which they are bound, R′ and... Agent: Bayer Healthcare LLC

20080026995 - Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers: The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20080026999 - Two-component bacillus lantibiotic and methods for producing and using the same: The present invention relates to two-component lantibiotics isolated from Bacillus sp. Methods for producing said lantibiotics are provided, wherein dehydration and cyclization of the peptides is carried out by two substrate-specific modifying enzymes. Given the antimicrobial activity of the instant lantibiotics, methods for preventing or treating bacterial infections are also... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20080026992 - Tyrosine phosphorylation of cdk inhibitor proteins of the cip/kip family: The present invention is directed to tyrosine phosphorylated forms of Cip/Kip proteins including p27Kip1, fragments of these forms and antibodies thereto. The invention is further related to non-phosphorylatable forms of Cip/Kip proteins, or fragments thereof. Further embodiments are diagnostic or therapeutic uses of the disclosed compounds, in particular uses in... Agent: Wilson Sonsini Goodrich & Rosati

20080027005 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells: This application discloses compositions and methods for treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on multimeric peptides.... Agent: Goodwin Procter LLP

20080027006 - Compositions and methods for modification and prevention of sars coronavirus infectivity: The invention relates to diseases of coronaviruses, particularly severe acute respiratory syndrome (SARS). Compositions and methods in connection with peptide-based compounds are described relating to inhibition or prevention of coronavirus activity including that of SARS coronavirus and the ability of its S protein to achieve fusion with and entry into... Agent: Greenlee Winner And Sullivan P C

20080027008 - Antitumorigenic drug combination: Compositions comprising drugs having cooperative activity and methods of treatment using the combinations are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20080027009 - Surfactant preparation having reduced enzyme damaging: A method of protecting skin enzymes from the harmful effects of a cosmetic cleansing preparation which comprises water and one or more anionic surfactants. The method comprises using a cleansing preparation which has a pH value of from 4 to 7 and an SCTE (Stratum Comeum Tryptic Enzyme) value, determined... Agent: Greenblum & Bernstein, P.L.C

20080027014 - Novel sglt inhibitors: m

20080027016 - Cancer treatment application of genomic replacement therapy: Genomic Replacement Therapy uses the human genome found in mantle dentin of a patient's tooth to affect other cells of the body. Mantle Dentin cells in the developed tooth do not reproduce, therefore the DNA is “younger”. Replacing the genome of the affected area with a “younger” one will hopefully... Agent: John M Pavelchik

20080027018 - Electrotransfer of nucleic acid into tissue cells: n

20080027015 - Methods and materials for modulating enac-beta: The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of ENaC-beta. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding ENaC-beta.... Agent: Fish & Richardson P.C.

20080027017 - Spinal and nerve application of genomic replacement therapy: Genomic Replacement Therapy uses the human genome found in mantle dentin of a patient's tooth to affect other cells of the body. Mantle Dentin cells in the developed tooth do not reproduce, therefore the DNA is “younger”. Replacing the genome with a “younger” one will hopefully aid in the treatment... Agent: John M Pavelchik

20080027026 - Composition for the treatment of inflammatory conditions: A novel treatment for topical inflammatory conditions such as acne, eczema, shingles, insect bites and hives is provided, consisting of the application of a pharmaceutical cream or ointment which incorporates hydroxypropyl methylcellulose acetate succinate (“HPMCAS”) in a micronized form and which preferably contains one or more thickeners, a bio-adhesive agent... Agent: Gottlieb Rackman & Reisman PC

20080027028 - Ketopyrroles useful as ligands in organic iridium compositions: wherein R2 is independently at each occurrence a deuterium atom, a halogen, a nitro group, an amino group, a C3-C40 aromatic radical, a C1-C50 aliphatic radical, or a C3-C40 cyclcoaliphatic radical; “a” is an integer from 0 to 3; and X1 and X2 are independently at each occurrence a bromine... Agent: General Electric Company Global Research

20080026985 - Control of gene expression: A method of suppressing the expression of a selected gene in a eukaryotic cell the method comprising introducing into the cell (a) a polypeptide comprising a DNA binding portion which binds to a site at or associated with the selected gene which site is present in a plant or animal... Agent: Nikolai & Mersereau, P.A.

20080026984 - Methods for treating inflammatory disease by administering aldehydes and derivatives thereof: A method is disclosed for treating inflammatory disease in an animal in need thereof by administering to the animal a pharmaceutical composition containing an anti-inflammatory effective amount of an organic aldehyde compound or a derivative thereof in a pharmaceutically acceptable vehicle.... Agent: Wolf Greenfield & Sacks, P.C.

20080026986 - Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling: CD8+ regulatory T (Treg) cells and γδ Treg cells profoundly suppress host immune responses and thus protect against autoimmune disease while restricting desired immune responses such as antitumor immunity. Synthetic phosphorothioate-protected, guanosine-containing oligonucleotides can directly reverse the suppressive activity of Treg cells without involving dendritic cells. This effect appears to... Agent: Fulbright & Jaworski, LLP

20080026987 - Use of liver-selective glucokinase activators: The present invention provides a method of normalizing blood glucose levels in mammals utilizing liver-selective glucokinase activators. The present invention also provides a method of increasing liver metabolism and decreasing apoptosis independent of glucose normalization or hyperglycemic conditions.... Agent: Novo Nordisk, Inc. Patent Department

20080026988 - Compositions and methods for human immunodeficiency virus vaccination: The present invention relates to methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods of inducing an immune response to human immunodeficiency virus (HIV) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising HIV or antigenic... Agent: Medlen & Carroll, LLP

20080026989 - Human ependymin: The present invention relates to a novel human Ependymin protein which is a member of the ependymin family. In particular, isolated nucleic acid molecules are provided encoding the human Ependymin protein. Ependymin polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080026991 - Compositions containing quaternary ammonium compounds: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at... Agent: Young & Thompson

20080027000 - Apo-a-i regulation of t-cell signaling: The invention provides AFTI polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing AFTI polypeptides. Also provided are methods for the treatment, diagnosis, amelioration, or prevention of diseases with AFTI polypeptides, particularly IL-1 mediated diseases, TNF-α mediated... Agent: Fulbright & Jaworski L.L.P.

20080027002 - Compositions and methods for targeting cancer-specific transcription complexes: The invention provides molecules that target cancer-specific transcription complexes (CSTC), compositions and kits comprising CSTC-targeting molecules, and methods of using CSTC-targeting molecules for the treatment) detection and monitoring of cancer.... Agent: Karen S. Canady Canady & Lortz LLP

20080026998 - Human kunitz-type inhibitor with enhanced antifibrinolytic activity: A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2).... Agent: Mueting, Raasch & Gebhardt, P.A.

20080026997 - Medicament for the treatment of fungal infections particularly aspergillosis: The combination of pentraxin PTX3 with antifungal agents is described for the treatment of fungal infections and particularly for infections caused by Aspergillus fumigatus. Thanks to the synergistic effect of the two drugs, the combination allows the administration of suboptimal doses of antifungal agent.... Agent: Nixon & Vanderhye, PC

20080026993 - Modified growth hormones: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.... Agent: Fish & Richardson, PC

20080026994 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C.

20080027001 - Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same: The present invention provides novel isolated and purified polynucleotides and polypeptides related to functional motifs of the Nogo receptor 1 (NgR1) (e.g., the binding pocket on the side surface of NgR1, functional motifs comprising the amino acid sequence of FRG, etc.) and use of peptides mimicking these functional motifs as... Agent: Fitzpatrick Cella Harper & Scinto

20080026996 - Selective vpac2 receptor reptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20080027003 - Peptides useful for treating gnrh associated diseases: A peptide comprising at least one hydrophobic moiety attached to an amino acid sequence capable of binding a GnRH receptor, the amino acid sequence being at least 11 amino acids in length. Also provided are methods of using such peptides for the treatment of GnRH-associated diseases.... Agent: Martin D. Moynihan Prtsi

20080027004 - Phosphorylated cop1 molecules and uses thereof: The invention provides COP1 molecules and modulators of COP1 activity and methods of using them, including diagnostic and therapeutic uses thereof. Such molecules can be useful for detecting DNA damage and modulating the response to DNA damage and p53 activity in subjects. The invention also provides reagents and kits for... Agent: Heller Ehrman LLP

20080027007 - Control of radiation injury: The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides... Agent: Trask Britt

20080027010 - Treatment of refractory cancers using na+/k+-atpase inhibitors: The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+/K+-ATPase inhibitors, such as cardiac glycosides, including bufadienolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080027012 - Bridged carbamate macrolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20080027011 - Homogeneous paste and gel formulations: This invention provides for a pharmaceutical or veterinary paste or gel formulation which may comprise an effective amount of a therapeutic agent; optionally an absorbent or a viscosity modifier; optionally a hydrophilic carrier, a colorant, stabilizer, surfactant, or preservative and optionally an antioxidant, solvent, flavoring, buffering system or thickener and... Agent: Judy Jarecki-black, Ph.d.,j.d.

20080027013 - Antibacterial treatment of osteoarthritis: The present invention relates to use of an antibacterial agent in the manufacture of a medicament for the treatment of osteoarthritis, more particularly for the treatment of a bacterial infection which is responsible for osteoarthritis. Also described are methods for the diagnosis of osteoarthritis through the detection of certain bacteria... Agent: Needle & Rosenberg, P.C.

20080027020 - Human neuropeptide receptor: Human neuropeptide receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080027019 - Oligonucleotide compositions and methods for the modulation of the expression of b7 protein: Compositions and methods for the treatment of asthma with oligonucleotides which specifically hybridize with nucleic acids encoding B7 proteins.... Agent: Knobbe, Martens, Olson & Bear, LLP

20080027021 - Use of cpg oligodeoxynucleotides to induce angiogenesis: This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This... Agent: Klarquist Sparkman, LLP

20080027022 - Method to treat gastric lesions: The present invention provides a therapeutic method for treating gastric lesions, including administration to a patient in need thereof of an effective amount of an A2A adenosine receptor agonist. The A2A adenosine receptor agonist can be a compound of formula (I) as disclosed herein. The invention further provides a therapeutic... Agent: Schwegman, Lundberg & Woessner, P.A.

20080027023 - Antiproliferative compositions comprising aryl substituted xylopyranoside derivatives: Novel xylose based glycoside compounds that have xylose linked O-, S- or C-glycosidically to an aglycone containing several aromatic rings, and compositions that comprise the novel xylose based glycosides and non-xylose-based anti-tumor agents, pharmaceuticals or dietary supplements. The compounds or compositions are administered to treat proliferative diseases, including various forms... Agent: Young & Thompson

20080027024 - Dietary supplement and methods of use: One aspect of the invention provides dietary fiber compositions comprising effective amounts of glucomannan, xanthan gum, and alginate to produce a desired viscosity. The invention also provides food products comprising an effective amount of a dietary fiber composition. In other aspects, the invention provides methods for preparing a dietary fiber... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080027025 - Protection from and treatment of prion protein infection: The disclosure for the first time provides an understanding of the mechanism of prion protein infection: prion proteins contain a cationic protein transduction domain (PTD) that interacts with the cell surface such that it induces macropinocytosis and enters the cytoplasm.... Agent: Buchanan, Ingersoll & Rooney LLP

20080027027 - Lactosucrose high content saccharide, its preparation and uses: The present invention solves above objects by providing a lactosucrose high content saccharide comprising 70% or more of lactosucrose and less than 3% of the total amount of 1-kestose and fructosyl lactosucrose, on a saccharide composition basis; a process for producing the lactosucrose high content saccharide, comprising the steps of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080027029 - Cold menthol receptor-1 antagonists: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or... Agent: Philip S. Johnson Johnson & Johnson

20080027030 - Pharmaceutical compositions comprising amifostine and related compounds: The present invention is directed to pharmaceutical compositions comprising amifostine or a related compound and a compound which may be selected from the group consisting of an anesthetic, a corticosteroid, an antihistamine and an anti-inflammatory. The present invention is also directed to methods of treating or protecting tissue of a... Agent: Jones Day

20080027031 - Retinoids and related compounds for the treatment of neuroinflammatory conditions, diseases and disorders: The proliferation and activation of microglia is emerging as an important etiologic factor and target for therapeutic intervention in several CNS diseases, including Alzheimer's disease and multiple sclerosis. Here, we have discovered that retinoic acids dramatically inhibit microglial proliferation in an in vivo model including the widely-used animal model of... Agent: Morgan, Lewis & Bockius, LLP

20080027032 - Combinations comprising cox-2 inhibitors and aspirin: A pharmaceutical composition is provided for treatment of conditions in mammals which are responsive to COX-2 inhibition which comprises in combination a COX-2 inhibitor and low-dose aspirin for simultaneous, sequential or separate use... Agent: Novartis Corporate Intellectual Property

20080027033 - Method and composition for treatment of cutaneous lesions: A method of treatment or prophylaxis of a cutaneous lesion in an animal the method comprising topically applying to an area of skin of the animal a composition comprising: one or more metal chelators; one or more transforming growth factor modulators; and one or more dermal penetration enhancers.... Agent: Foley And Lardner LLP Suite 500

20080027034 - Ciclesonide and syk inhibitor combination and method of use thereof: The invention relates to pharmaceutical formulations containing combinations of ciclesonide and a syk inhibitor and the use of such pharmaceutical compositions in medicine, in particular in the prophylaxis and treatment of respiratory disease.... Agent: Nath & Associates PLLC

20080027035 - Dpp-iv inhibitors: e

20080027036 - S1p receptor modulating compounds and use thereof: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune... Agent: Goodwin Procter LLP Patent Administrator

20080027038 - N-acylated lipophilic amino acid derivatives: Compounds of structural formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which... Agent: Nixon & Vanderhye, PC

20080027037 - Cyclic compounds: wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted),... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080027039 - Method for treating a motor neuron disease: According to the present invention, there is provided a method for treating a motor neuron disease, comprising the step of administering a therapeutically effective amount of a compound having serotonin receptor antagonist activity or its pharmacologically acceptable salt or their solvate optionally together with a pharmaceutically acceptable carrier to a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080027040 - Oxazolidinone-quinolone hybrid antibiotics: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:... Agent: Edwards Angell Palmer & Dodge LLP

20080027041 - Pyridizinone derivatives: e

20080027042 - Novel aminopyridine derivatives having aurora a selective inhibitory action: wherein m1 and m2 are 1, 2, or 3; n1 and n2 are 0 or 1; i is an integer of any of 1 to m1; j is an integer of 1 to m2; R is aryl, heteroaryl, or cycloalkyl any of which may be substituted; Rai and Rai′ is... Agent: Merck And Co., Inc

20080027043 - Preparation of antimicrobial formulations using 7-oxa-2-thia-1,5-diazabicyclo[3.3.1]nonane-2,2-dione: Use of 7-oxa-2-thia-1,5-diazabicyclo[3.3.1]nonane-2,2-dione (“cyclotaurolidin”) for the preparation of antimicrobial formulations, in particular antimicrobial solutions for technical or medical purposes and of aqueous lock solutions for catheters and port systems for preventing infections and sepsis of patients.... Agent: Henry M. Feiereisen Henry M. Feiereisen, LLC

20080027044 - Prodrug antibiotic screens: Methods for identifying prodrug activity utilizing screens with microbial mutants, including null and conditional mutants, transiently gene-repressed microbes, and gene-overexpressing microbes, as well as pooled collections of these are provided. Effective prodrug antibiotics differentially kill or inhibit microbes overexpressing prodrug activating genes and allow non-expressing strains to grow and be... Agent: Wilmerhale/boston

20080027045 - 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents: The present invention provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080027046 - Synergistic mixtures of anthranilamide invertebrate pest control agents: and a component (b) wherein the component (b) is at least one compound or agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080027047 - Compounds that modulate hsp90 activity and methods for identifying same: The present invention relates to compositions and methods related to inhibitors of Hsp90, including substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080027048 - 2-phenylthiophene derivative: The present invention relates to a 2-phenylthiophene derivative or a salt thereof, wherein the thiophene ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at the... Agent: Sughrue-265550

20080027049 - Benzofurans as potassium ion channel modulators: e

20080027050 - Heterocyclic amide compound and use thereof as an mmp-13 inhibitor(amended ex officio): The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted... Agent: Edwards Angell Palmer & Dodge LLP

20080027052 - Methods for treating cystic kidney disease: The present invention relates to methods for treating or preventing cystic kidney diseases or disorders using calcimimetics and pharmaceutically acceptable salts of these compounds. Various aspects related to treating mammal including humans. Still other aspects related to various formulations including combination formulation that may be used to treat kidney disease... Agent: Sommer Barnard Attorneys,p.c.

20080027051 - Novel heteroaryl substituted benzoxazoles: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzoxazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080027053 - Antimicrobial oxazolidinone prodrugs: This invention includes oxazolidinone prodrug compounds of Formula (I) and Formula (II) as defined herein. The prodrugs are convertible by natural biological processes into an active ingredient possessed of antimicrobial properties useful in treating bacterial infections in mammals.... Agent: Philip S. Johnson Johnson & Johnson

20080027055 - 1-aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080027054 - 4-substituted quinolines as antitumor agents: The invention concerns compounds of formula (I), wherein each of R1, R2, R3, R4, R5, R6, R8, R9, R10 m, n, p, X, Y and Z have any meanings defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament... Agent: Morgan Lewis & Bockius LLP

20080027056 - Substituted heterocyclic ethers and their use in cns disorders: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080027057 - Use of dihydroimidazolones for the treatment of dogs: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1 H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.... Agent: Fulbright & Jaworski, LLP

20080027058 - Mitotic kinesin inhibitors: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080027059 - Substituted isoxazolines, pharmaceutical compositions containing same, methods of preparing same, and uses of same: in which A, R1, R2, R3, R4, Z, X, m, n, and p, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted isoxazolines, to methods of preparing said substituted isoxazolines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of... Agent: Millen, White, Zelano & Branigan, P.C.

20080027060 - Dipeptide nitriles: In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080027061 - Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Millen, White, Zelano & Branigan, P.C.

20080027062 - 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level: The present invention relates to the area of NO synthase inhibition and, more particularly, relates to novel 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing said compounds, and the use of said compounds in the treatment of a disorder characterized by a disturbed nitric oxide level.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080027063 - Imidazopyrazines as protein kinase inhibitors: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080027064 - Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them: The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds... Agent: Fulbright & Jaworski, LLP

20080027065 - Compounds: e

20080027066 - Arylpiperazinyl compounds: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural... Agent: Goodwin Procter LLP Patent Administrator

20080027068 - Heterocyclic compounds and thrombopoietin receptor activators: wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080027067 - Heterocyclic derivatives as modulators of ion channels: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20080027069 - Quinazoline compounds: The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is —O—, —NH— or —S—; n is 0-5; m is 0-3; R1 and R2 are defined herein including groups: (i) Q1X1 wherein Q1 and X1 are as... Agent: Morgan Lewis & Bockius LLP

20080027070 - 2-amino--5-substituted pyrimidine inhibitors: Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases.... Agent: Dla Piper US LLP

20080027071 - Novel heteroaryl derivatives, their preparation and use: A heteroaryl derivative having the formula (I). The compounds of the invention are considered useful for the treatment of affective disorders such as general anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders, and neurological disorders such as psychosis.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080027072 - Potentiation of mc4 receptor activity: The present invention provides methods of treating obesity, eating disorders, and sexual dysfunction. The methods comprise administering to a mammalian host suffering from obesity, an eating disorder, or sexual dysfunction an effective dose of a compound of the invention. Also provided are methods of potentiating the effect of an MC4... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080027073 - Substituted indanyl sulfonamide compounds, their preparation and use as medicaments: e

20080027074 - 2-(1h-indolysulfanyl)-aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence: The present invention relates to aniline derivatives of the general formula I as the free base or salts thereof and their use.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080027075 - Quaternary amino-function chalcones: The present invention provides novel quaternary amino-functional chalcone derivatives and analogues exhibiting interesting antibacterial activity. The compounds have the general formula (Y1)m—Ar1(X1)—C(=O)VAr2(X2)−(Y2)p (I), wherein V designates —CH2—CH2—, —CH═CH— or —C≡C—; Ar1 and Ar2 independently are aryl and heteroaryl; m=0, 1, 2, p=0, 1, 2, m+p>0; each Y1 and Y2 independently... Agent: Edwards Angell Palmer & Dodge LLP

20080027076 - Pyrimidines with tie2 (tek) activity: The invention relates to a compound of the Formula (I); or salt thereof, wherein R1, R2, R3, R4, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and... Agent: Astrazeneca R&d Boston

20080027077 - Novel biaromatic compounds that modulate ppargamma type receptors and cosmetic/pharmaceutical compositions comprised thereof: e

20080027079 - Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity:

20080027078 - 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1h)one derivatives:

20080027080 - Cyclic derivatives as modulators of chemokine receptor activity: This invention relates generally to modulators of chemokine receptor activity having unexpected combination of desirable pharmacological properties. Pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and prevention of inflammatory, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases, particularly diabetes, Crohn's disease, atherosclerosis, and multiple... Agent: Louis J. Wille Bristol-myers Squibb Company

20080027081 - Therapeutic compounds: The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2′,3′-methylidene acetal adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to compounds that are pro-drugs of adenosine receptor agonists, and to their use as therapeutic... Agent: Edwards Angell Palmer & Dodge LLP

20080027082 - Use of adenosine a1 antagonists in radiocontrast media induced nephropathy: Described herein are pharmaceutical combinations comprising a therapeutically effective amount of a first selective adenosine A1 antagonist and a first radiocontrast media. In one embodiment the selective adenosine A1 antagonist comprises 4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-trans-cyclohexanol methanesulfonate and/or (4S)-4-hydroxy-1-(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-L-prolinamide methanesulfonate. Also described are the use of a first selective adenosine A1 antagonist in the... Agent: Mayer Brown LLP

20080027084 - Modulators of chemokine receptor activity crystalline forms and process: s

20080027083 - Modulators of chemokine receptor activity crystalline forms and process:

20080027085 - 2-(pyridin-2-yl)-pyrimidines and their use for controlling harmful fungi: The invention relates to 2-(pyridin-2-yl)-pyrimidine compounds of general formula (I) and their use for controlling pathogenic fungi and as plant protection products that, as an active constituent, contain compounds of this type, whereby: k represents 0, 1, 2, 3; m represents 0, 1, 2, 3, 4 or 5; n represents... Agent: Birch Stewart Kolasch & Birch

20080027086 - Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles: e

20080027087 - Cb1 antagonists and inverse agonists: The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080027088 - Imidazole-based hmg-coa reductase inhibitors: The present invention relates to methods of treating atherosclerosis, dyslipidemia, other cardiovascular diseases and related diseases, such as diabetes, using a serine palmitoyltransferase (SPT) inhibitor. The present invention also relates to pharmaceutical compositions and kits that comprise a serine palmitoyltransferase (SPT) inhibitor, optionally with another pharmaceutical agent.... Agent: Pfizer Inc.

20080027089 - Rapamycin derivatives and the uses thereof in the treatment of neurological disorders: e

20080027090 - Tetracyclic indoles as potassium channel modulators:

20080027091 - Soft anticholinergic zwitterions: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; and wherein each asterisk marks a chiral center; said compound having the R, S or RS stereoisomeric configuration at each chiral center unless specified otherwise, or being a mixture thereof.... Agent: Buchanan, Ingersoll & Rooney PC

20080027092 - 1-acetic acid-indole, -indazole and -benzimidazole derivatives useful for the treatment of respiratory disorders: The present invention relates to substituted indoles of formula (I) useful as pharmaceutical compounds for treating respiratory disorders.... Agent: Fish & Richardson P.C.

20080027093 - Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel cyclohexylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also... Agent: Merck And Co., Inc

20080027094 - Tropane compounds and pharmaceutical compositions comprising the same as an active ingredient: e

20080027095 - Use of 3-substituted-2-(diphenylmethy)-1-azabicyclo[2.2.2]octanes for treating mrg-x1 receptor mediated diseases: The invention encompasses a method for treating a disease or condition mediated by the human MRG-X1 receptor, such as nociception, hyperalgesia, allodynia, pain related to central hypersensitivity conditions, somatic pain, visceral pain, acute pain, chronic pain, post-operative pain, headache, inflammatory pain, neurological pain, musculoskeletal pain, cancer related pain or vascular... Agent: Merck And Co., Inc

20080027096 - Novel pharmaceutical compositions: The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, for use in the treatment or prophylaxis of condition mediated by an androgen receptor.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080027098 - Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation: e

20080027097 - Pharmaceutical drug candidates and methods for preparation thereof: The present invention is directed to methods of preparation of sulfonate derivatized compounds, e.g., 3-amino-1-propanesulfonic acid and 1,3-propanedisulfonic acid disodium salt with increased purity, with reduced potential for toxic by-products, and that are pharmaceutically useful, e.g., for the treatment of amyloidosis.... Agent: Lahive & Cockfield, LLP

20080027099 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080027100 - Functionally selective alpha2c adrenoreceptor agonists: In its many embodiments, the present invention provides a novel class of indolines as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080027102 - Quinolinyl-pyrrolopyrazoles: A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound.... Agent: Eli Lilly & Company

20080027101 - Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound: c

20080027103 - Novel crystalline forms 1: The present invention relates to 6-(4-{[(benzylsulfonyl)amino]carbonyl}piperidin-1-yl)-5-cyano-2-methylnicotinic acid isopropyl ester, form II, to a process for preparing such compound, to its utility as P2Y12 inhibitor and as anti-thrombotic agent etc, its use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing it.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080027104 - Novel crystalline forms 2: The present invention relates to 6-(4-{[(benzylsulfonyl)amino]carbonyl}piperidin-1-yl)-5-cyano-2-methylnicotinic acid ethyl ester, form I and II, to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080027105 - Dosing regimen of flavopiridol for treating cancer`: A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080027106 - Methods of treating psychosis and schizphrenia based on polymorphisms in the cntf gene: This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders.... Agent: Novartis Corporate Intellectual Property

20080027107 - Antharquinone compounds as anti cancer compounds: Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which R1 to R4 are each selected from the group consisting of H, C1-4 alkyl, X1, —NHR0N (Rs)2 in which R° is a C1l12 alkanediyl and each R5 is H or optionally substituted C14 alkyl, and... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080027108 - Therapeutic substituted lactams: t

20080027109 - Cetp activity inhibitors: wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted... Agent: Leydig Voit & Mayer, Ltd

20080027110 - Indolyl-3-glyoxylic acid derivatives having antitumor action: and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080027111 - Treatment and prevention of cardiovascular disease using mast cell stabilizers: The present invention is directed to methods of treating or preventing the development of cardiovascular disease by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing cardiovascular disease.... Agent: Law Office Of Michael A. Sanzo, LLC

20080027112 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080027113 - Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits... Agent: Jones Day

20080027114 - Active agent combinations with insecticidal and acaricidal properties: The invention relates to novel insecticidal active compound combinations comprising, firstly, cyclic ketoenols or other acaricidally active compounds and, secondly, further insecticidally active compounds from the group of the anthranilamides, which combinations are highly suitable for controlling animal pests, such as insects and unwanted acarids.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080027115 - Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof: The present invention relates to solid phase or solution phase combinatorial libraries of autoinducer analogs. The present invention also relates to autoinducer agonists and antagonists. In addition, the present invention relates to methods for identifying autoinducer agonists and antagonists, as well as methods for regulating the activity of an autoinducer... Agent: Nixon Peabody LLP - Patent Group

20080027116 - Pharmaceutical composition for treating spinocerebellar ataxia: e

20080027117 - Antifungal azole derivatives having a fluorovinyl moiety and process for the preparation thereof: An azole derivative of formula (I) having a fluorovinyl moiety or a pharmaceutically acceptable salt thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has advantageously low toxicity.... Agent: Anderson, Kill & Olick, P.C.

20080027118 - Prodrugs of mitotic kinesin inhibitors: The present invention relates to prodrugs of dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080027119 - Methods and compositions employing bicifadine for the treatment of acute pain, chronic pain, and symptoms of neuropathic disorders: Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat acute pain, chronic pain, and symptoms associated with neuropathic disorders.... Agent: Black Lowe & Graham, PLLC

20080027120 - Ketorolac tromethamine compositions for treating or preventing ocular pain: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.... Agent: Allergan, Inc.

20080027122 - Indole derivatives: m

20080027121 - Novel pyrone-indole derivatives and process for their preparation: The present invention relates to novel pyrone-indole derivatives, pharmaceutical formulations containing them, and use of the compounds in the manufacture of Medicaments for treating or preventing various diseases.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080027123 - (+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dione:methods of using and compositions thereof: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the... Agent: Jones Day

20080027124 - 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase i: as inhibitors of human casein kinase Iε, and methods of using said compounds of formula (I) and formula (II) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. The R-group substituents are defined herein and pharmaceutical compositions comprising compounds of formula (I) or formula (II)... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080027125 - Fluvastatin sodium novel forms and preparation thereof: Provided are a novel solid states of fluvastatin sodium and processes for preparation thereof.... Agent: Kenyon & Kenyon LLP

20080027126 - Pyrrolidin-2-one derivatives for use as dp1 receptor agonists: The present invention is directed to compounds that may be used as agonists of prostaglandin receptors. More specifically, the specification describes methods and compositions for making and using DP1 receptor agonists that are pyrrolidin-2-one derivatives.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080027127 - Trans pyrrolidinyl derivates and their pharmaceutical use: R1, R2 or R3 are hydrogen or a carboxy or amino protecting group; R4 to R8 represent hydrogen or an alkyl radical; R9 represents a (R10)n(—R11)m group wherein R10 is —CO—, —CS—, —O—, —S—, —SO—, —SO2—, —COO—, —CONRa—, —N(Ra)CO—, —CSNRa—, —N(Ra)CS—, —N(Ra)—, Rb, aryl, and R11 is a polar group,... Agent: Young & Thompson

20080027128 - Duloxetine hcl polymorphs: A crystalline form of duloxetine hydrochloride, pharmaceutical compositions of the crystalline form of duloxetine hydrochloride, and methods of preparing the crystalline form of duloxetine hydrochloride are provided.... Agent: Kenyon & Kenyon LLP

20080027129 - Administration of 3h-1, 2-dithiole-3-thione, anethole dithiolethione, sulforaphane, phenethyl isothiocyanate, 6-(methylsulfinyl)hexyl isothiocyanate and allyl isothiocyanate for the treatment of canities: At least one compound selected from among 3H-1,2-dithiole-3-thione, anethole dithiolethione, sulforaphane, phenethyl isothiocyanate, 6-(methylsulfinyl)hexyl isothiocyanate and allyl isothiocyanate and derivatives and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative conditions of the scalp, plant extracts having propigmenting activity and active agents... Agent: Buchanan, Ingersoll & Rooney PC

20080027130 - Cytotoxic agents comprising taxanes and their therapeutic use: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent... Agent: Sughrue Mion, Zinn, Macpeak & Seas, PLLC

20080027131 - Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity: The present invention is a method for the treatment of obesity, for promoting weight loss and/or suppressing appetite comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) as herein defined.... Agent: Philip S. Johnson Johnson & Johnson

20080027132 - Materials and methods for treating coagulation disorders: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080027133 - Use of chromen-4-one derivatives: where R1 and R2 may be identical or different and are selected from H, —C(═O)—R7, —C(═O)—OR7, alkyl groups, alkenyl groups, hydroxyalkyl groups and/or cycloalkyl groups and/or cycloalkenyl groups, R3 is H or alkyl groups, R4 is H or OR8, R5 and R6 are selected from —H, —OH, alkyl groups, alkenyl... Agent: Millen, White, Zelano & Branigan, P.C.

20080027134 - Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use: e

20080027135 - Methods for identifying chemical modulators of ras superfamily gptase activity: The present invention provides a method of identifying a compound having the ability to modulate the guanine nucleotide exchange cycle of a Ras superfamily GTPase, comprising: a) contacting the compound with a guanine nucleotide exchange factor and a GTPase and obtaining a baseline fluorescence measurement; b) contacting the guanine nucleotide... Agent: Myers Bigel Sibley & Sajovec

20080027136 - Compositions and methods for the treatment of cystic fibrosis: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20080027137 - Synthesis scheme for lacosamide: e

20080027138 - Novel niddm regimen: The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent.... Agent: Novo Nordisk, Inc. Patent Department

20080027139 - Use of alpha-ketoglutarate and related compounds: The use of at least one member selected from alpha-ketoglutaric acid, glutamine, glutamic acid and pharmaceutically acceptable salts of these acids, amides of alpha-ketoglutaric acid with an amino acid or di- or tripeptide, dipeptides of glutamine and another amino acid, tripeptides of glutamine and other amino acids, dipeptides of glutamine... Agent: Ladas & Parry LLP

20080027140 - Combinations of serotonin reuptake inhibitors and imidazoline i ² agonists: The present invention relates to combinations of serotonin reuptake inhibitors and imidazoline I2 agonists as separate chemical units or both properties combined in a single molecule and to the use thereof for the preparation of medicaments for the treatment of depression, obsessive-compulsive disorders (OCDs), obsessive-compulsive spectrum disorders (OCSDs) and other... Agent: Millen, White, Zelano & Branigan, P.C.

20080027141 - 1,3-dihydroxyl-9,10-anthraquinone and 3-[(3-amino)-propoxy]- 9,10-anthraquinone derivatives and pharmaceutical compositions comprising the same: Disclosed herein are 1,3-dihydroxyl-9,10-anthraquinone and 3-[(3-amino)-propoxy]-9,10-anthraquinone derivatives, in particular 1,3-dihydroxy-4-prenyl-9,10-anthraquinone and 3-[3-(4-methylpiperazinyl)-propoxy]-9,10-anthraquinone, which are found to have inhibitory activities against several types of human tumor/cancer cells and thus can be used in the manufacture of pharmaceutical compositions for use in the treatment of tumors/cancers.... Agent: Townsend And Townsend And Crew, LLP

20080027142 - System cleaner concentrate: The invention relates to a concentrate for cleaning and disinfection which comprises (i) one or more alkyl alcohol alkoxylates, (ii) one or more formaldehyde donor compounds, (iii) optionally one or more biocidal, in particular fungicidal, active ingredient(s), (iv) optionally one or more glycols and (v) optionally up to 10% by... Agent: Young & Thompson

20080027143 - Chemical formulation for an insecticide: A chemical formulation for an insecticide comprises an active material and a solvent with a viscosity of less than or equal to about 4 centistokes at 25 degrees Celsius, wherein the solvent does not cause damages to a surface. The solvent also has a low gum content to minimize the... Agent: S.c. Johnson & Son, Inc.

20080027144 - Benzonaphthacene glycoside derivative and use thereof: A dicarboxylic acid compound obtainable by oxidative degradation of pradimicin antibiotics, which are antibiotics consisting of the benzonaphthacene skeleton, a D-amino acid side chain and a sugar chain, for the second saccharide residue of the sugar chain, and use thereof utilizing a specific microorganism binding property thereof are provided. The... Agent: Birch Stewart Kolasch & Birch

20080027145 - Therapeutic molecules and methods for generating and/or selecting same: The present invention relates generally to therapeutic molecules useful for inducing apoptosis of particular cells such as, but not limited to, cancer cells and methods for generating and/or selecting same. The present invention further provides methods for inducing apoptosis of cells such as cancer cells and pharmaceutical compositions useful for... Agent: The Mccallum Law Firm, P. C.

20080027148 - Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the enzyme peptides, and methods of identifying... Agent: Celera

20080027146 - Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases: The invention provides genetic markers of periodontal disorders and/or periodontal diseases. The present invention provides methods and compositions to aid in the detection, diagnosis, treatment and monitoring of periodontal disorders and/or periodontal diseases.... Agent: Banner & Witcoff, Ltd.

20080027147 - Novel human transferase family members and uses thereof: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host... Agent: Millennium Pharmaceuticals, Inc.

20080020964 - Test system for the discovery of substances for the promotion of neuraxonal growth: The invention relates to a method for identifying or testing active substances, which influence the growth and survival of nerve cells, wherein a cell is brought into contact with at least one substance and subsequently, within said cell, the mRNA of the β-actin or the β-actin protein alone or together... Agent: Mayer & Williams PC

20080020966 - Novel bacillus thuringiensis gene with coleopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Coleoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20080020968 - Novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20080020967 - Unique novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20080020975 - Galanin receptors and brain injury: There is provided the use of a GALR2-specific agonist in the preparation of a medicament for the prevention or treatment of brain injury, damage or disease, wherein the brain injury or damage is caused by one of: embolic, thrombotic or haemorrhagic stroke; direct or indirect trauma or surgery to the... Agent: Hunton & Williams LLP Intellectual Property Department

20080020981 - Non-nucleoside reverse transcriptase inhibitors: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, X1 and X2 are as herein defined. Also disclosed in the present invention are... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080020987 - Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes: e

20080020991 - Methods of treating, reducing, or preventing autoimmune conditions: The present invention relates to methods and kits for treating, reducing, or preventing autoimmune conditions such as rheumatoid arthritis by administering to a mammal in need thereof an agent that modulates the expression level or biological activity of Toll-like receptor-9 (TLR-9). Also disclosed are screening methods that make use of... Agent: Clark & Elbing LLP

20080020990 - Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same: The present invention relates to oligo double-stranded RNAs for use in knockdown of the expression of Bcl-2 protein known as a suppressor for apoptosis, and pharmaceutical compositions containing them. It is known that Bcl-2 protein is over-expressed in diseases such as cancer, and by this over-expression, the growth of cancer... Agent: Darby & Darby P.C.

20080020996 - Esters of capsaicin for treating pain: e

20080021000 - Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species: Mixtures of natural phosphatidylcholine species, natural lysophosphatidylcholine species, phosphatidylserine species, phosphatidylethanolamine species, 1-hydroxy-2-acyl-phosphatidylcholine species, 1-hydroxy-2-acyl-phosphatidylserine molecular species, 1-hydroxy-2-acyl-phosphatidylethanolamine molecular species, 1-O-alkyl-2-hydroxy phosphatidylcholine species, 1-O-alkyl-2-docosaheaxnoyl phosphatidylcholine species 1-O-alkyl-2-docosahexaenoyl phosphatidylserine species, and 1-O-alkyl-2-docosahexaenoyl phosphatidylethanolamine species, Methods using the above disclosed mixtures in mammals to treat various conditions.... Agent: Law Office Of Michael A. Blake

20080020969 - 36 human secreted proteins: The present invention relates to 36 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080020965 - Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region... Agent: Banner & Witcoff, Ltd.

20080020970 - Somatostatin antagonists: The present invention is directed to a somatostatin antagonist according to formula (I), wherein A1 is an optionally substituted aromatic ax-amino acid; A2 is an optionally substituted aromatic α-amino acid; A3 is Dab, Dap, Lys or Orn; A4 is β-Hydroxyvaline, Ser, Hser, or Thr; A5 is an optionally substituted D-... Agent: Alan F. Feeney, Esq.

20080020971 - Heptanoic acid derivatives as dipeptidyl peptidase inhibitors: The present invention is directed to novel heptanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080020972 - Use of human chorionic gonadotropin orally for the treatment of overweight (obesity) associated with high blood tension, non-insulin-dependent diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy: Human Chorionic Gonadotropin administered by intramuscular route is traditionally used for the treatment of sterility and cryptorchidism. After numerous tests performed, a compound to be administered orally—sublingual—has been developed with such drug to treat patients suffering from overweight associated with high blood tension, non-insulin-dependant diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy. The... Agent: Belluscio, Daniel Oscar

20080020973 - Assays for identification of topoisomerase inhibitors: The instant invention provides a continuous spectroscopic assay for DNA topoisomerase activity. The invention further provides topoisomerase inhibitors and pharmaceutical compositions for the treatment of topoisomerase associated diseases and disorders.... Agent: Edwards Angell Palmer & Dodge LLP Client: Jhu

20080020974 - Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x: The present invention relates to a method of treating insulin resistance or Syndrome X. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. The invention also includes pharmaceutical compositions comprising a somatostatin or somatostatin agonist and the use... Agent: Biomeasure, Incorporated

20080020976 - Antimicrobially active peptide: An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.... Agent: Knobbe Martens Olson & Bear LLP

20080020978 - Cgrp peptide antagonists and conjugates: Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also disclosed is a method of producing the composition of matter. Methods of... Agent: Amgen Inc.

20080020980 - Magnesium ammonium phosphate cement composition: This invention relates to a cement, which comprises in its main phase of microcrystalline magnesium ammonium phosphate and nanoapatite after hardening and thus at the same time has considerable strength. The material is biologically degradable and is suitable for application in tooth cements, as bone replacement, as bone filler, as... Agent: Townsend And Townsend And Crew, LLP

20080020982 - Methods and compositions for treatment of atherosclerosis: The present invention provides methods and compositions for treating subject having atherosclerosis. The invention provides a method comprising administering to a subject having atherosclerosis an effective amount of insulin like growth factor-1 (IGF-1), wherein the administering is effective to treat atherosclerosis in the subject. The invention also provides kits for... Agent: Bozicevic, Field & Francis LLP

20080020979 - Peptides of syndecan-1 for inhibiting angiogenesis: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.... Agent: Fulbright & Jaworski L.L.P.

20080020983 - Peptides with antioxidant and antimicrobial properties: One embodiment of the present invention is directed toward methods for inhibiting the oxidation of lipids, proteins, and other compounds. Another embodiment is directed toward methods for treating conditions associated with microbial contamination, colonization, and/or infection.... Agent: Dinsmore & Shohl, LLP

20080020977 - Use of fullerenes to oxidize reduced redox proteins: Disclosed herein is a method of oxidizing a reduced redox protein by contacting an aqueous solution containing the reduced redox protein with a water-soluble substituted fullerene under conditions in which the water-soluble substituted fullerene can oxidize the reduced redox protein. The redox protein can be cytochrome c.... Agent: Williams, Morgan & Amerson

20080020984 - Crystal structure of a receptor-ligand complex and methods of use: The invention relates to the three-dimensional structure of a crystal of an EphB4 receptor complexed with a ligand. The three-dimensional structure of a Receptor